Improvements in Clinical Cancer Care Associated with Integration of Personalized Medicine

Arushi Agarwal; Daryl Pritchard; Alissa Winzeler; Hina Mohammed; Thomas D Brown; Gary G Gustavsen

doi:10.3390/jpm14090997

Improvements in Clinical Cancer Care Associated with Integration of Personalized Medicine

J Pers Med. 2024 Sep 20;14(9):997. doi: 10.3390/jpm14090997.

Authors

Arushi Agarwal¹, Daryl Pritchard², Alissa Winzeler^{3

4}, Hina Mohammed³, Thomas D Brown³, Gary G Gustavsen⁵

Affiliations

¹ Health Advances LLC, San Francisco, CA 94105, USA.
² Personalized Medicine Coalition, Washington, DC 20036, USA.
³ Syapse, West Chester, PA 19380, USA.
⁴ Private Health Management, Los Angeles, CA 90024, USA.
⁵ Health Advances LLC, Newton, MA 04266, USA.

Abstract

Background: While adoption of personalized medicine (PM) continues to increase in clinical oncology, there is limited data connecting the level of PM adoption at a given institution to improved clinical outcomes for patients. The purpose of this study was to analyze the correlation between health care providers' scores on a previously described PM integration framework and two outcome measures: the use of targeted therapy and clinical trial enrollment.

Methods: This study was conducted using real-world data (RWD) from the Syapse^® Learning Health Network (LHN). The PM integration score for six community hospital systems in the LHN was calculated and subsequently correlated with the two outcome measures.

Results: Across six institutions, a strong correlation between PM integration score and targeted therapy use was observed in metastatic non-small cell lung cancer (mNSCLC) (R² = 0.81), an indication with a significant number of approved targeted agents. Conversely, a strong correlation between PM integration score and clinical trial enrollment was observed in metastatic triple-negative breast cancer (TNBC) (R² = 0.63), an indication with fewer marketed targeted therapies but an active targeted therapy pipeline.

Conclusion: The results in these cases suggest that PM integration is a strong indicator of high-quality care practices for both utilization of targeted therapy in more mature PM indications (e.g., mNSCLC) and clinical trial enrollment in more emerging PM indications (e.g., TNBC).

Keywords: clinical trials; maturity model; personalized medicine; precision medicine; targeted therapies.

Grants and funding

This study was supported through a contract with the Personalized Medicine Coalition, a 501(c)(3) nonprofit organization headquartered in Washington, DC, representing industry, scientists, patients, providers and health insurers.